{"id":3226,"date":"2023-05-24T22:49:16","date_gmt":"2023-05-24T20:49:16","guid":{"rendered":"https:\/\/jacked.sk\/obchod\/hexarelin\/"},"modified":"2026-08-21T14:28:29","modified_gmt":"2026-08-21T12:28:29","slug":"hexarelin-5mg","status":"publish","type":"product","link":"https:\/\/dev.jacked.sk\/en\/research-on-muscle-growth\/hexarelin-5mg\/","title":{"rendered":"Hexarelin 5 mg"},"content":{"rendered":"
\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Hexarelin 5 mg \u2013 The Most Potent GHRP Secretagogue for GH Research and Cardioprotection<\/h1>\n

\u26a0\ufe0f Warning:<\/strong> This product is intended solely for scientific research purposes<\/strong> (research use only<\/em>). It is not intended for use as a medicine, drug, dietary supplement, or for human use. Sale restricted to individuals over the age of 18.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

What is Hexarelin?<\/h2>\n

Hexarelin is a<\/strong> synthetic hexapeptide<\/strong> (6 amino acids) belonging to the class of GH secretagogues (GHRP \u2013 Growth Hormone-Releasing Peptides)<\/strong>. Within this class of compounds, hexarelin is considered one of the most potent GH secretagogues<\/strong> based on the results of preclinical and clinical pharmacokinetic studies.
\nChemically, it is a modified hexapeptide with the following sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH\u2082<\/strong>, which contains D-amino acids that increase its metabolic stability against enzymatic degradation.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Synthetic hexapeptide: structure and classification within the GHRP class<\/h3>\n

GHRP (Growth Hormone-Releasing Peptides) are a group of synthetic peptides that stimulate the release of GH by acting on the ghrelin receptor (GHS-R1a). In addition to Hexarelin, this class includes GHRP-2<\/strong>, GHRP-6<\/strong>, and Ipamorelin<\/strong>, each of which exhibits a distinct pharmacological profile and potency.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Mechanism of action: GHS-R1a and GH secretion<\/h2>\n

The primary mechanism of action of Hexarelin is its agonism at the GHS-R1a (Growth Hormone Secretagogue Receptor 1a)<\/strong> \u2014a receptor that is identical to the ghrelin receptor. Activation of this receptor on somatotrophic cells of the pituitary gland leads to the release of endogenous growth hormone (GH)<\/strong>.
\nThe mechanism involves activation of the phosphoinositide signaling pathway (PKC), which leads to an increase in intracellular Ca\u00b2\u207a and subsequent exocytosis of secretory granules containing GH.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Potency Compared to Other GHRP’s<\/h3>\n

Based on preclinical studies, Hexarelin exhibits significantly higher GH-stimulating activity compared to other members of the GHRP class:<\/p>\n\n\n\n\n\n\n\n
GHRP compound<\/strong><\/td>\nRelative Potency (GH Secretion)<\/strong><\/td>\nEffect on cortisol\/prolactin<\/strong><\/td>\n<\/tr>\n
Hexarelin<\/strong><\/td>\n\u2605\u2605\u2605\u2605\u2605 (highest)<\/td>\nYes \u2013 increased cortisol and prolactin<\/td>\n<\/tr>\n
GHRP-2<\/td>\n\u2605\u2605\u2605\u2605\u2606<\/td>\nMild effect<\/td>\n<\/tr>\n
GHRP-6<\/td>\n\u2605\u2605\u2605\u2606\u2606<\/td>\nMild effect, strong effect on ghrelin<\/td>\n<\/tr>\n
Ipamorelin<\/td>\n\u2605\u2605\u2605\u2606\u2606<\/td>\nHigh selectivity \u2013 minimal impact<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Note: The table is based on preclinical pharmacokinetic data. The relative potency is approximate. <\/em>
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Unique Feature: Cardioprotective research independent of GH<\/h2>\n

The most significant and scientifically innovative aspect of Hexarelin is its cardioprotective mechanism<\/strong>, which has been documented in preclinical studies as being independent of GH secretion<\/strong>.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Binding to the CD36 receptor in cardiomyocytes<\/h3>\n

In addition to GHS-R1a, hexarelin binds to CD36<\/strong> \u2014a scavenger receptor expressed on the surface of cardiomyocytes, macrophages, and other cells\u2014and to a truncated form of the GHS-R receptor<\/strong> present in cardiac tissue. This binding mediates direct cardioprotective effects independent of pituitary GH secretion.
\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n

Preclinical Studies: Ischemia, Reperfusion, and Apoptosis of Cardiomyocytes<\/h3>\n

In preclinical studies using isolated hearts (Langendorff model) and animal models, Hexarelin was investigated in the context of:<\/p>\n